Reid Hoffman, co-founder of LinkedIn and a long-time board member at Microsoft, is stepping down to focus on his new venture, Manus, an AI-powered drug discovery company. This move underscores the growing trend of prominent tech figures returning to operational roles in AI startups, even while maintaining connections to major tech corporations.
What Happened
Microsoft announced Hoffman’s departure on June 5, 2026. He joined Microsoft’s board following the $26.2 billion acquisition of LinkedIn in 2016 and played a role in key Microsoft decisions, including the $1 billion investment in OpenAI in 2019 and the $650 million deal with Inflection AI, which brought Mustafa Suleyman to Microsoft. Hoffman previously stepped down from OpenAI’s board in 2023 to avoid conflicts of interest. He is now refocusing on Manus, where he serves as chairman of the board, with Dr. Siddhartha Mukherjee as CEO. Manus has already raised over $50 million in seed funding.
Why It Matters
This shift signals a significant trend: established tech leaders are actively re-engaging with early-stage AI ventures. Hoffman described his decision as a move to go “founder mode,” driven by the progress he's seeing at Manus. The company's focus on “Move 37” AI—AI that surpasses human capabilities in chemical innovation, particularly in cancer treatment—is particularly noteworthy. The potential impact on drug discovery is substantial; AI could dramatically accelerate the identification of promising drug candidates and reduce the time and cost associated with bringing new therapies to market.
For developers, this could mean increased demand for skills in areas like machine learning, bioinformatics, and computational chemistry. The success of companies like Manus will likely drive further investment in these fields. For enterprises, it highlights the competitive pressure from nimble AI startups and the importance of fostering internal innovation to avoid disruption. The fact that Hoffman was involved in Microsoft's initial OpenAI investment and Inflection AI acqui-hire suggests a strategic awareness of the AI landscape, and his departure may subtly shift Microsoft’s priorities.
What To Watch
It will be crucial to observe Manus's progress in developing and deploying its “Move 37” AI platform. The efficacy of the AI in discovering novel drug candidates and navigating the complex regulatory landscape of pharmaceutical development remains to be seen. Also important to watch is how Hoffman's departure impacts Microsoft's long-term AI strategy and whether other prominent board members will follow suit to pursue founder roles in emerging tech startups. The broader implications of these shifts for the venture capital market and the flow of talent between established companies and AI startups also warrant attention.